Dong-A hikes R&D budget in 2010

Published: 2012-02-22 06:59:00

Updated: 2012-02-22 06:59:00

Dong-A Pharmaceutical Co., Korea’s No.1 pharmaceutical firm, said it spent 8 percent of its revenue on research and development (R&D) last year, up 0.6 percentage points from R&D budget in 2010.

“The increasing investment in R& D is one of measures to transform Dong-A into an inventor of rolli...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK